SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination
with SCT510 in patients with HCC who have not received prior systemic therapy.